Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Says USPTO Upholds Claims in Liver Cancer Drug Patent


Alnylam Pharmaceuticals this week announced that the US Patent and Trademark Office has upheld certain claims within a company patent covering the use of siRNAs against kinesin spindle protein, the target of the company's phase I liver cancer drug ALN-VSP.

According to Alnylam, the patent, No. 7,718,629, was challenged by Tekmira Pharmaceuticals' subsidiary Protiva Biotherapeutics. Alnylam and Tekmira are currently embroiled in a legal dispute over the rights to siRNA delivery technology (GSN 3/17/2011).

"The maintained claims in the KSP RNAi patent cover the siRNA composition of matter used in ALN-VSP and define the relevant claims for further development and commercialization of this promising RNAi therapeutic for liver cancers," Alnylam CBO Laurence Reid said in a statement.

As part of their dispute, Alnylam has alleged that Tekmira filed a patent application on an siRNA sequence claimed in the '629 patent. The USPTO is now set to review the priority dates for the companies' respective intellectual property, it added.

In a statement, Tekmira President and CEO Mark Murray characterized the USPTO decision as a victory for his company.

"At this stage of the proceedings, the [patent office] denied or deferred all four of Alnylam's motions and granted two of our three motions, including our motion that Alnylam's broad claims are unpatentable due to lack of adequate written description support,” he said.

“Alnylam's corresponding motion that Protiva's claims are unpatentable for lack of written description support was denied, as was their motion that Protiva is not entitled to priority benefit based on our provisional applications,” Murray added. “Moving forward, we believe Tekmira has earlier priority on the remaining claims, which will be determined in the next phase of the interference proceedings.”

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.